Comparing the effects of simultaneous and separate use of magnesium and inositol tablets on symptoms of polycystic ovary syndrome

Study of the simultaneous effect of inositol and magnesium on improving clinical and ultrasound symptoms in patients with polycystic ovary syndrome: A randomized clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251201068169N1

Enrollment

124

Registered

2025-12-07

Start date

2025-12-22

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention group:.

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Willingness to participate in the study Age 20-45 years People who meet two of the three criteria for polycystic ovary syndrome according to the Rotterdam criteria (menstrual cycle disorders (amenorrhea, oligomenorrhea), clinical hyperandrogenism, sonographic appearance of polycystic ovaries (presence of 20 or more follicles in each ovary with a diameter of 2-9 mm and an increase in ovarian volume to more than 10 mm)) desire to get pregnant being married

Exclusion criteria

Exclusion criteria: Having diabetes mellitus Having high blood pressure Having cardiovascular diseases Having thyroid disorders Having kidney disease Pregnant or breastfeeding women Taking oral contraceptives Use of hormonal medications in the past 2 months Taking lipid-lowering medications Male factor infertility

Design outcomes

Primary

Measure	Time frame
The size of mature follicles in each ovary. Timepoint: Before the start of the study, on day 11-12 of the menstrual cycle for three consecutive cycles. Method of measurement: Transvaginal ultrasound.	—

Secondary

Measure	Time frame
Pregnancy success. Timepoint: If menstruation does not occur in any of the three cycles examined, pregnancy success will be assessed. Method of measurement: Human chorionic gonadotropin hormone assay.;Body mass index. Timepoint: Before the start of the study and if pregnancy does not occur at the end of the third month. Method of measurement: scales.;Hirsutism score. Timepoint: Before the start of the study and if pregnancy does not occur at the end of the third month. Method of measurement: Freeman-Galway criterion.;The number of mature follicles in each ovary. Timepoint: Before the start of the study and on days 11-12 of the menstrual cycle for three consecutive months. Method of measurement: Transvaginal ultrasound.;Acne severity. Timepoint: Before the start of the study and if pregnancy does not occur at the end of the third month. Method of measurement: Based on the Global Acne Grading Scale.	—

Measure

Time frame

Pregnancy success. Timepoint: If menstruation does not occur in any of the three cycles examined, pregnancy success will be assessed. Method of measurement: Human chorionic gonadotropin hormone assay.;Body mass index. Timepoint: Before the start of the study and if pregnancy does not occur at the end of the third month. Method of measurement: scales.;Hirsutism score. Timepoint: Before the start of the study and if pregnancy does not occur at the end of the third month. Method of measurement: Freeman-Galway criterion.;The number of mature follicles in each ovary. Timepoint: Before the start of the study and on days 11-12 of the menstrual cycle for three consecutive months. Method of measurement: Transvaginal ultrasound.;Acne severity. Timepoint: Before the start of the study and if pregnancy does not occur at the end of the third month. Method of measurement: Based on the Global Acne Grading Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZAHRA MAKIVANDI

Yasouj University of Medical Sciences

ZAHRAMAKIVANDI@GMAIL.COM+98 61 5272 1106

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026